<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439854</url>
  </required_header>
  <id_info>
    <org_study_id>5 R01 DK024092-27/NIH Prot IV</org_study_id>
    <secondary_id>R01DK024092</secondary_id>
    <nct_id>NCT01439854</nct_id>
  </id_info>
  <brief_title>Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action</brief_title>
  <acronym>DAPA MITO</acronym>
  <official_title>Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of the chronic treatment of type 2
      diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin
      signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a
      potent, highly specific inhibitor of renal glucose transport [SGLT2].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Glucotoxicity&quot; has been implicated as a cause of insulin resistance and impaired beta cell
      function in T2DM. Abundant support for the glucotoxicity hypothesis has been provided by in
      vivo and in vitro studies in animals, but a rigorous test of this hypothesis in man is
      lacking. The investigators propose to test the glucotoxicity hypothesis by chronically
      reducing the plasma glucose in type 2 diabetic subjects (T2DM) with an inhibitor of renal
      glucose transport, dapaglifozin, and examining the effect of restoration of normoglycemia on
      mitochondrial function and insulin signaling/sensitivity. Lastly, the investigators will test
      the &quot;glucolipotoxicity&quot; hypothesis, which states that the toxic effects of elevated plasma
      FFA on insulin sensitive tissues (i.e., muscle) are magnified in the presence of concurrent
      hyperglycemia. Thus, high glucose levels increase malonyl CoA, which inhibits CPT I, leading
      to accumulation of FACoA/DAG, which impair mitochondrial function and inhibit insulin action.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>baseline, two weeks</time_frame>
    <description>The change in insulin sensitivity and total glucose disposal measured at two weeks with the insulin clamp compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mitochondrial Function</measure>
    <time_frame>baseline, two weeks</time_frame>
    <description>The change in mitochondrial function/gene expression at two weeks compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Multiple Mitochondrial Dysfunctions Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this arm is control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Treatment arm, 10 mg per day for 2 weeks</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients are treated with placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2DM

          -  Drug Naive Or On Oral Therapy

        Exclusion Criteria:

          -  Insulin Treatment

          -  Major Organ Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Division, UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2011</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ralph DeFronzo</investigator_full_name>
    <investigator_title>Professor, Medicine -Diabetes</investigator_title>
  </responsible_party>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Mitochondrial function</keyword>
  <keyword>Glucose toxicity</keyword>
  <keyword>Glucosuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

